DeepMed Research

Abramson Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.pennmedicine.org

Clinical Trials

FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer

Phase 1

Completed

Conditions: Rectal Cancer
Colon Cancer
Metastasis
Adenocarcinoma

First Posted Date: 2010-09-22

Last Posted Date: 2019-04-18

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 50

Registration Number: NCT01206530

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Cardiotoxicity of Cancer Therapy (CCT)

Conditions: Breast Cancer

Interventions: Diagnostic Test: Echocardiography
Other: Blood Collection
Other: Symptoms Questionnaire

First Posted Date: 2010-08-02

Last Posted Date: 2025-02-04

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 700

Registration Number: NCT01173341

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

BCRL Prevention Pilot

Completed

Conditions: Obesity
Breast Cancer

First Posted Date: 2010-07-21

Last Posted Date: 2012-10-12

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 20

Registration Number: NCT01166672

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Physical Functional Side Effects of Taxane Chemotherapy for Breast Cancer

Completed

Conditions: Breast Cancer

First Posted Date: 2010-06-30

Last Posted Date: 2020-03-10

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 25

Registration Number: NCT01153282

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Autologous OC-DC Vaccine in Ovarian Cancer

Early Phase 1

Completed

Conditions: Chemotherapy
Tumor
Ovarian Cancer

First Posted Date: 2010-05-27

Last Posted Date: 2018-06-11

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 67

Registration Number: NCT01132014

Locations: 🇺🇸
Ovarian Cancer Research Center, Philadelphia, Pennsylvania, United States

Proton Radiotherapy for Recurrent Tumors

Not Applicable

Completed

Conditions: Tumors

Interventions: Other: Proton Radiotherapy

First Posted Date: 2010-05-19

Last Posted Date: 2020-04-24

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 24

Registration Number: NCT01126476

Locations: 🇺🇸
ProCure Proton Therapy Center, Warrenville, Illinois, United States
🇺🇸
Procure, Oklahoma City, Oklahoma, United States
🇺🇸
Abamson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Single Nucleotide Polymorphism (SNP) Panels and Risk Assessment in Women Undergoing Mammography

Completed

Conditions: Mammography

First Posted Date: 2010-05-14

Last Posted Date: 2019-03-07

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 1600

Registration Number: NCT01124019

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Combination Gene Transfer and Chemotherapy

Phase 1

Completed

Conditions: Mesothelioma

Interventions: Drug: SCH 721015

First Posted Date: 2010-05-07

Last Posted Date: 2020-03-17

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 40

Registration Number: NCT01119664

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Proton Radiation For Meningiomas and Hemangiopericytomas

Phase 1

Completed

Conditions: Meningioma
Hemangiopericytoma

Interventions: Radiation: Proton Radiation

First Posted Date: 2010-05-06

Last Posted Date: 2024-11-07

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 53

Registration Number: NCT01117844

Locations: 🇺🇸
Abramson Cancer Center of the Unviersity of Pennsylvania, Philadelphia, Pennsylvania, United States

Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)

Phase 1

Terminated

Conditions: Acute Myelogenous Leukemia (AML)

Interventions: Drug: Eltrombopag

First Posted Date: 2010-04-30

Last Posted Date: 2021-08-05

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 44

Registration Number: NCT01113502

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy